Market Access

Pharmacy benefit reform in Medicaid addresses drug transparency

Clarivate U.S. market access experts discuss recent Medicaid policy changes in some states meant to control drug costs and increase transparency. Read more. In recent years, state governments began to notice rising costs of drugs and hidden charges associated with them. As state and federal governments contribute to a large portion of Medicaid expenses, they […]

Healthcare consolidation paves way for care delivery changes

Clarivate U.S. market access experts discuss on recent mergers, cause of these mergers and their impact on the healthcare system. Read more.  Changes in the U.S. healthcare industry, many of which were prompted by the pandemic, are driving consolidations to cover gaps in care and stabilize revenue streams. Payers are engaging in non-traditional mergers, such as the announcement by UnitedHealth Group’s Optum unit to buy Change Healthcare to strengthen its analytics, technology and revenue cycle management capabilities. Payers […]

Type 2 diabetes in Mainland China: Shifting treatment patterns

Mainland China has gone through a series of regulatory and reimbursement reforms in recent years in an effort to keep pace with its dynamic economic and demographic landscape. Clarivate market assessment expert Karan Verma discusses the role of these reforms in Mainland China’s type 2 diabetes market and how they could broaden access to innovative […]

Volume-Based Procurement in Mainland China: Key trends and planning future strategies

Mainland China has gone through a series of regulatory and reimbursement reforms in recent years in an effort to keep pace with its dynamic economic and demographic landscape. Clarivate expert Karan Verma discusses how the Volume-Based Procurement program is transforming the generics landscape, increasing patient access and prompting manufactures to rethink strategies.   Remodeling Mainland […]

Amazon and Walmart wade into U.S. telehealth and digital pharmacy

The e–commerce giants’ evolving healthcare offerings could put pressure on drug makers, as well as PBMs and telehealth vendors Amazon’s healthcare ambitions have long been the subject of intense speculation – and not a little anxiety – for players throughout the sector. Amazon’s massive scale and world-beating digital capabilities give it the power to disrupt nearly any business it enters. So you could almost hear healthcare company CEOs taking a sharp breath and sitting up a little straighter when, in March, Amazon announced that it would offer its in-house health […]

State review boards take on drug prices amid Congressional inaction

How are states tackling high drug prices and increasing affordability? Clarivate market access expert Stephanie Hoops discusses the emergence of affordability review boards. Done waiting for Congress to take action on drug prices, states are increasingly enacting laws that create drug affordability review boards. As is done with utilities or insurance premiums, the boards allow states […]

How the pandemic has impacted the Federal Health Insurance Exchange in the U.S.

In the United States, as the COVID-19 pandemic shuttered non-essential businesses, millions lost their jobs and with them, employer-sponsored health coverage. This drove a spike in the rate of uninsured patients, along with a shift from commercial employer-sponsored plans to other coverage options, such as coverage bought through state- and federal government-run health insurance exchanges, Medicaid and short-term health insurance plans.   Implemented as part of the 2010 Affordable Care Act reforms, health insurance exchanges vary from state […]

Mainland China’s anticipated biosimilar boom – potential and key drivers of the market

The market of major biologics in Mainland China has tripled since 2017, with the potential to grow five-fold over the next ten years – which could drive biosimilars growth. Clarivate expert Akash Saini discusses this market’s potential and key drivers.    The approval of Shanghai Henlius Biotech’s HLX01—a biosimilar of rituximab (Roche’s MabThera)—in February 2019 […]